Lecture on Juno's Cell Handling Platform for Efficient Production of Gene-Modified T Cells
We are excited to announce the next talk of our CellGenix Lecture series given by Dr. Lothar Germeroth. With our CellGenix Lectures we want to provide insights in the latest advances in the cell and gene therapy, and the regenerative medicine field.
CAR T cells have shown very promising clinical efficacy in patients with haematological malignancies. Driven by the clinical benefits a substantial future demand has to be satisfied by products with very complex production procedures. Standardization, productivity, and scalability are prerequisites to generate high-quality cell products in sufficient quantities.
Juno is developing a cell handling platform which addresses the main questions in CAR T cell production to meet future demands. New Juno technologies such as T-Catch, Expamers and Streptamers will be discussed in the context of an efficient production platform.
Lothar Germeroth, PhD
Managing Director Juno Therapeutics GmbH
SVP Juno Therapeutics, Inc.
Juno Therapeutics GmbH, Göttingen
More information on Juno Therapeutics
Monday, 7 November 2016
followed by a drinks reception with pretzels and wine
am Flughafen 16
Please register before 1 November 2016 at Lectures@cellgenix.com or 0761/88 88 9-0